Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds

Sep 11, 2007

A genetic variant present in nearly half of Americans of European ancestry is linked to greater effectiveness of the smoking cessation medication bupropion (Zyban), according to research by scientists supported by the National Institute on Drug Abuse (NIDA) and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

People with this variant were less likely than those without it to have resumed smoking six months after treatment with bupropion.

The study, published in the September issue of the journal Biological Psychiatry, is a step toward the goal of being able to tailor smoking cessation treatment to individuals based on their unique genetic make-up.

"This study is part of our ongoing commitment to develop more accurate and personalized approaches to medicine," said NIH Director Dr. Elias A. Zerhouni. "This kind of genetic research is helping us to better understand why some people respond to certain smoking cessation treatments, and others don't."

Source: National Institute on Drug Abuse

Explore further: Technology translation engine launches 'Organs-on-Chips' company

add to favorites email to friend print save as pdf

Related Stories

Neanderthals' genetic legacy

Jan 29, 2014

Remnants of Neanderthal DNA in modern humans are associated with genes affecting type 2 diabetes, Crohn's disease, lupus, biliary cirrhosis and smoking behavior. They also concentrate in genes that influence ...

Scientist takes first step to measure chromium contamination

Apr 29, 2013

Judy Zelikoff is filling an unwanted role. Three decades after hexavalent chromium spread under a Garfield, N.J., neighborhood, this accomplished scientist and her team of researchers at New York University may finally be ...

Recommended for you

User comments : 0